Gary Graham
Psychiatric/Mental Health · Westland, MINPI 1992129704
Payments from drug & device makers
Across 161 payments — averaging $23.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$924
- Lundbeck LLC$485
- Indivior Inc.$455
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$424
- AbbVie$397
- Alkermes, Inc.$288
- plus $766 from 10 others
What the payments were for
- Food & beverage$3,69499%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 28 | $924 |
| Lundbeck LLC | 23 | $485 |
| Indivior Inc. | 21 | $455 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $424 |
| AbbVie | 25 | $397 |
| Alkermes, Inc. | 11 | $288 |
| Sunovion Pharmaceuticals Inc. | 15 | $206 |
| Axsome Therapeutics, Inc. | 7 | $160 |
| Johnson & Johnson | 7 | $134 |
| Vanda Pharmaceuticals Inc. | 6 | $129 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Neurocrine Biosciences, Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $14 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,740 in reported general payments places this provider in the 85th percentile of 638 psychiatric/mental health providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 26 | $42,256 |
| VraylarCariprazine Hcl | 12 | $16,393 |
| Aripiprazole | 21 | $330 |
| Trazodone Hcl | 36 | $327 |
| Bupropion XlBupropion Hcl | 11 | $267 |
| Duloxetine Hcl | 12 | $218 |
| Clonazepam | 15 | $197 |
| Mirtazapine | 21 | $195 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $192 |
| Sertraline Hcl | 13 | $186 |
| Olanzapine | 20 | $158 |
| Fluoxetine Hcl | 11 | $119 |
| Hydroxyzine Pamoate | 14 | $117 |
| Risperidone | 16 | $98 |
| Quetiapine Fumarate | 14 | $98 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $924 | $42,25626 claims |
| AbbVieVraylar | $397 | $16,39312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 638 psychiatric/mental health providers in Michigan.
Other psychiatric/mental health in Westland
- Duren GutierrezSouthfield$207K
- Tamlynn EvansTraverse City$78K
- Shiba NixonClarkston$60K
- Amy AmesClinton Township$43K
- Cody ShinavierClarkston$41K
- Oksana LidkeBattle Creek$30K
- Jennifer Wims-MaddenPontiac$28K
- Jessica ShantzWarren$21K
- Gladys KimeliSaginaw$17K
- Cynthia MaiSaginaw$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.